Financial Performance - Revenue for the six months ended June 30, 2022, was €315,626 thousand, a decrease of 1.3% compared to €319,678 thousand in 2021[10] - Gross profit for the same period was €142,554 thousand, reflecting a decline of 10.8% from €159,825 thousand in 2021[10] - Adjusted gross profit was €144,279 thousand, down 11.7% from €163,367 thousand in the previous year[10] - Profit for the period decreased by 33.7% to €43,467 thousand, compared to €65,578 thousand in 2021[10] - Adjusted net profit after tax was €53,537 thousand, a decrease of 28.2% from €74,575 thousand in the prior year[10] - The company reported an adjusted gross margin of 45.7% for the first half of 2022, compared to 49.1% in the same period of 2021[10] - The adjusted net profit margin after tax was 17.0% for the six months ended June 30, 2022, down from 23.3% in 2021[10] - Total revenue for the six months ended June 30, 2022, was HKD 315,626, a decrease of 1.1% from HKD 319,678 in the same period of 2021[31] - Gross profit for the same period was HKD 142,554, down 10.8% from HKD 159,825 in 2021[31] - Operating profit decreased to HKD 72,770, a decline of 25.0% compared to HKD 96,922 in the previous year[31] - Net profit for the period was HKD 43,467, representing a decrease of 33.7% from HKD 65,578 in 2021[31] - EBITDA for the six months ended June 30, 2022, was HKD 114,584,000, compared to HKD 133,813,000 for the same period in 2021, reflecting a decline of approximately 14.4%[85] - The total expenses for the six months ended June 30, 2022, amounted to HKD 243,198,000, up from HKD 224,187,000 in 2021, which is an increase of 8.5%[111] Market Expansion and Future Outlook - The company is focusing on expanding its market presence and enhancing its service offerings in the eye care sector[10] - Future outlook includes plans for new clinic openings and potential acquisitions to drive growth[10] - The acquisition of London Vision Clinic Partners Limited is expected to contribute to growth targets as outlined in the share purchase agreement[192] Asset and Liability Management - Non-current assets increased to HKD 717,868 as of June 30, 2022, from HKD 412,186 at the end of 2021, representing a growth of 74.0%[26] - Total assets reached HKD 1,533,406, up from HKD 1,369,022 at the end of 2021, indicating an increase of 12.0%[26] - Total liabilities increased to HKD 531,355 as of June 30, 2022, compared to HKD 328,545 at the end of 2021, reflecting a growth of 62.0%[28] - Non-current liabilities rose to HKD 348,522, up from HKD 186,066, marking an increase of 87.2%[28] - Current liabilities totaled HKD 182,833, an increase of 28.4% from HKD 142,479 in the previous year[28] - The company’s total liabilities related to leases increased significantly, with minimum lease payments totaling HKD 332,385 million as of June 30, 2022, compared to HKD 243,990 million as of December 31, 2021, marking a 36.4% increase[162] Cash Flow and Investment Activities - Cash generated from operating activities was HKD 108,775,000, a decrease from HKD 143,592,000 in the previous period, reflecting a decline of approximately 24.3%[42] - The net cash used in investing activities amounted to HKD (118,166,000), significantly higher than HKD (16,567,000) in the prior period, indicating increased investment outflows[42] - The company reported a decrease in cash and cash equivalents of HKD (73,869,000), compared to an increase of HKD 89,882,000 in the previous period[42] - The company acquired a subsidiary for HKD (91,453,000), which contributed to the increase in cash outflows from investing activities[42] Shareholder Returns and Dividends - The company paid dividends totaling HKD (33,097,000) during the period, compared to HKD (9,838,000) in the same period last year, indicating a significant increase in dividend payouts[42] - Basic earnings per share decreased to HKD 14.029 for the six months ended June 30, 2022, down from HKD 19.829 in 2021, reflecting a decline of 29.5%[123] Operational Challenges - The COVID-19 pandemic and related control measures significantly affected operations in major Chinese cities, leading to a temporary suspension of business in Shanghai from late March to early June 2022[191] - Following the easing of strict COVID-19 measures in China, the group's business gradually returned to pre-COVID levels, with outpatient consultation volumes recovering[191] Segment Performance - The German segment generated revenue of HKD 181,794,000, while the Chinese segment contributed HKD 48,749,000, indicating a significant difference in performance across regions[85] - Revenue from vision correction services for the six months ended June 30, 2022, was HKD 313,086,000, a slight decrease of 1.85% from HKD 318,677,000 in the same period of 2021[99] - The Danish segment showed significant growth, with revenue increasing to HKD 54,088,000 in the first half of 2022 from HKD 33,741,000 in the previous year, marking a growth of 60.3%[97]
德视佳(01846) - 2022 - 中期财报